Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Allergan Acquires Chin Fat Drug Firm
by Rick Mullin
June 22, 2015
| A version of this story appeared in
Volume 93, Issue 25
Allergan has agreed to acquire Kythera in a cash and equity deal valued at approximately $2.1 billion. Allergan is the drug firm formerly called Actavis. Known for Botox, it will add Kythera’s newly approved Kybella (deoxycholic acid), an injectable drug providing nonsurgical treatment for submental fullness, better known as double chin. “The acquisition of Kythera is a strategic investment that strengthens our leading global position in aesthetics,” says Allergan CEO Brent Saunders. Kythera also has a drug for male-pattern baldness in early-stage development.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter